N/A
Completed N=4,918
Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities
Pulmonary Disease, Chronic Obstructive
Source: ClinicalTrials.gov NCT00621582 ↗
Enrolled (actual)
4,918
Serious AEs
0.1%
Results posted
Jun 2010
Primary outcomePrimary: Patient Global Assessment of Chronic Obstructive Pulmonary Disease (COPD) Symptom at Visit 1 and Visit 3 (Number of Patients Whose Assessment Were Excellent and Good) — 831; 4213 Participants — p=0.01
Summary
The objective of the present Post Marketing Surveillance Study (PMS) study is to evaluate safety and effectiveness of tiotropium bromide (Spiriva®) 18 µg once daily in 5,000 patients with COPD of varying severities over 8 weeks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Patient Global Assessment of Chronic Obstructive Pulmonary Disease (COPD) Symptom at Visit 1 and Visit 3 (Number of Patients Whose Assessment Were Excellent and Good) |
831; 4213 | 0.01 sig |
| PRIMARY Patient Tolerability Assessment at Visit 3 |
5; 196; 1570; 3109 | — |
| SECONDARY Physician Global Assessment of Spiriva Effectiveness at Visit 2 and Visit 3 (Number of Patients Whose Assessment Were Excellent and Good) |
4005; 4694 | — |
| SECONDARY Physician Tolerability Assessment at Visit 3 |
2; 90; 1112; 3676 | — |
Eligibility Criteria
Inclusion Criteria
Incl. Criteria Patients with clinical diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) according to definition of China COPD guideline.
Patients over 40 years old
Exclusion Criteria
Patient with history of hypersensitivity to tiotropium bromide, atropine and/or its derivant, i.e. ipratropium, or any component of Spiriva® Patient with known narrow-angle glaucoma
- Patient with known symptomatic prostatic hyperplasia and/or bladder-neck obstruction
- Patient with known moderate to severe renal impairment (i.e.,creatinin clearance<=50ml/min)
- Pregnant or nursing women
- Patient with any significant disease other than COPD which would exclude him/her from participating in the study
- Patients with any conditions listed in [special precautions], [drug interactions], and [contraindication] of Spiriva® China package insert
- Patients with signed informed consent of any other study
Data sourced from ClinicalTrials.gov (NCT00621582). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.